# Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

> **NCT03472586** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma
- Stage IV Uveal Melanoma AJCC v7

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Embolization Therapy

## Key facts

- **NCT ID:** NCT03472586
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472586, "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03472586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*